We are dedicated to helping patients who were severely vulnerable due to their lack of access to pharmaceutical-grade products, inadequate traceability, and limited information about Good Cultivation and Collection Practices (GACP) for medicinal plants.

Refractory epilepsy and many neurological disorders are very delicate to treat and have a significant impact on the family. We understand how essential it is for a family with a patient with severe conditions to receive a pharmaceutical product of proven quality, safety, and efficacy.

When we began working on cannabis in 2017, there were no cannabis-based pharmaceutical products marketed in the USA or Europe. Law 27350 had been passed in Argentina, which was aimed at generating research and development nationwide. Likewise, patients with conditions like refractory epilepsy did not have access to products appropriate for the severity of their condition, and their frustration—and that of their families—was completely understandable.